Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro20 (Hizentra) in dermatomyositis
NCT04044690Phase 3Terminated
- Sponsor
- CSL Limited
- Start
- Oct 2019
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
A Phase 3 trial of IgPro20 in dermatomyositis (DM), sponsored by CSL Limited. Started Oct 2019; status: terminated.
02
Drugs
IgPro20
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT04044690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044690.